Literature DB >> 26195695

Second-Line Therapy for Endometrial Cancer: The Need for Better Options.

Gini F Fleming1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26195695     DOI: 10.1200/JCO.2015.61.7225

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.

Authors:  Maurie Markman
Journal:  Womens Health (Lond)       Date:  2016-07

2.  Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).

Authors:  Emeline Moreira; Eduardo Paulino; Álvaro Henrique Ingles Garces; Mariane S Fontes Dias; Marcos Saramago; Flora de Moraes Lino da Silva; Luiz Claudio Santos Thuler; Andréia Cristina de Melo
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

3.  A Non-invasive Liquid Biopsy Screening of Urine-Derived Exosomes for miRNAs as Biomarkers in Endometrial Cancer Patients.

Authors:  Akhil Srivastava; Katherine Moxley; Rachel Ruskin; Danny Natarajan Dhanasekaran; Yan Daniel Zhao; Rajagopal Ramesh
Journal:  AAPS J       Date:  2018-07-09       Impact factor: 4.009

4.  Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.

Authors:  Dimitri Anzellini; Gianluca Arcangeli; Sergio Del Bianco
Journal:  Cancer Diagn Progn       Date:  2022-01-03

5.  How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.

Authors:  Brigida Anna Maiorano; Mauro Francesco Pio Maiorano; Gennaro Cormio; Annamaria Maglione; Domenica Lorusso; Evaristo Maiello
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

6.  Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.

Authors:  David M O'Malley; Giovanni Mendonca Bariani; Philippe A Cassier; Aurelien Marabelle; Aaron R Hansen; Ana De Jesus Acosta; Wilson H Miller; Tamar Safra; Antoine Italiano; Linda Mileshkin; Lei Xu; Fan Jin; Kevin Norwood; Michele Maio
Journal:  J Clin Oncol       Date:  2022-01-06       Impact factor: 50.717

Review 7.  Endometrial cancer.

Authors:  Vicky Makker; Helen MacKay; Isabelle Ray-Coquard; Douglas A Levine; Shannon N Westin; Daisuke Aoki; Ana Oaknin
Journal:  Nat Rev Dis Primers       Date:  2021-12-09       Impact factor: 65.038

Review 8.  Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.

Authors:  Ting-Tai Yen; Tian-Li Wang; Amanda N Fader; Ie-Ming Shih; Stéphanie Gaillard
Journal:  Int J Gynecol Pathol       Date:  2020-01       Impact factor: 3.326

Review 9.  Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations.

Authors:  Ioannis A Voutsadakis
Journal:  Clin Med Insights Oncol       Date:  2016-03-29

Review 10.  AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.

Authors:  Michael T Schweizer; Evan Y Yu
Journal:  Cancers (Basel)       Date:  2017-01-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.